News
Feedback from more than 35 patient groups has helped CADTH update its Guidance for Providing Patient Input — a key resource for patient groups, patients, and caregivers who contribute to our reimbursement review process.
The guide now addresses some of the key improvements suggested by patient groups, which include:
expanding the definition ...
Voretigene neparvovec (Luxturna) is the first gene therapy evaluated through the CADTH reimbursement review process
CADTH recommends reimbursement with conditions, including a price reduction, and offers advice on implementing the recommendation
On November 16, CADTH recommended that Canada’s federal, provincial, and territorial drug pla...
Did you miss some of the great live sessions during the 2020 Virtual CADTH Symposium?
Great news — our plenary and concurrent sessions are now available for on-demand viewing on the Symposium website.
In more great news, we’ve added 30 new pre-recorded sessions that will bring you fresh insights on a range of topics, including:
Artificial i...
After a Breakout Year for Digital Health, What’s Next?
This week, I’m proud to join Canadian health system leaders in celebrating Digital Health Week — a time to recognize how digital health is transforming the delivery of care.
When I think of the changes brought about by this pandemic, the “overnight” shift to virtual care stands out as amon...
Today CADTH presented Recognition Awards to two scientists to honour their exceptional contributions to the field of health technology assessment (HTA) — one as a pioneer who has pushed the boundaries of economic evaluation in child health and the other as a rising star who is advancing the use of real-world evidence in drug funding decisio...
